Germany
Spain
Japan
United States
This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of the products described within this website may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for each product in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy
This page contains a filterable bibliography of all publically available articles relating to afatinib and nintedanib. Please use the filters below to simplify your search.
Showing 1-10 of 303 Articles
| Title | Citation | Focus area | Phase | |
|---|---|---|---|---|
|
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas |
Norden AD, et al. J Neurooncol 2015;121(2):297-302 |
|
||
|
Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) |
Palmer D, et al. J Clin Oncol 2015;33(Suppl: Abstract 238) |
|
||
|
Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment |
Okusaka T, et al. Cancer Sci 2016;107:1791–1799 |
|
||
|
Rationale and design for the LUME-Colon 1 study: a randomised, double-blind, placebo-controlled Phase III trial of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with refractory colorectal cancer |
Van Cutsem E, et al. Clin Colorectal Cancer 2016;15(1):91-94.e1 |
|
||
|
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study |
Gottfried M, et al. J Clin Oncol 2017;12 (4): 475-485 |
|
||
|
Tumor growth over time in patients with non-small cell lung cancer (NSCLC) of adenocarcinoma histology (ACH) treated with nintedanib and docetaxel or placebo and docetaxel: analysis of data from the LUME-Lung 1 (LL1) study |
Reck M, et al. J Clin Oncol 2015;33(Suppl: Abstract e19021) | Non-squamous non-small cell lung cancer |
|
|
|
Tumor growth over time with nintedanib/docetaxel or placebo/docetaxel in adenocarcinoma NSCLC: analysis from the LUME-Lung 1 study |
Reck M, et al. J Thorac Oncol 2015;10(9 Suppl 2: Abstract MINI17.08) | Non-squamous non-small cell lung cancer |
|
|
|
Tumour growth over time in patients with advanced non-small cell lung cancer treated with nintedanib plus docetaxel or placebo plus docetaxel: analysis of data from the LUME-Lung 1 study |
Reck M, et al. Eur J Cancer 2015;51 (Suppl 3):S635-S636 | Non-squamous non-small cell lung cancer |
|
|
|
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer |
Gaschler-Markefski B, et al. ESMO Open 2017 [Epub ahead of print]. doi:10.1136/esmoopen-2016-000102 | Non-squamous non-small cell lung cancer |
|
|
|
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer |
Gaschler-Markefski B, et al. ESMO Open 2017 [Epub ahead of print]. doi:10.1136/esmoopen-2016-000102 | Non-squamous non-small cell lung cancer |
|